

MenHibrix® Available

Limited quantities available

MenHibrix® Available for the VFC Program

Hib-MenCY-TT (MenHibrix®, GlaxoSmithKline) will be available to order in very limited quantities through the Missouri Vaccines for Children (VFC) program starting February 1, 2014.

HibMenCY-TT is indicated for use only in infants 6 weeks through 18 months of age with recognized persistent complement component pathway deficiencies and infants who have anatomic or functional asplenia, including sickle cell disease. Hib-MenCY-TT is given as a 4-dose series at 2, 4, 6, and 12-15 months of age. If the first dose of Hib-MenCY-TT is given after 12 months of age, 2 doses should be given at least 8 weeks apart. HibMenCY-TT can be administered with other pediatric vaccines with the exception of Hib-containing vaccines. Additional details regarding Hib-MenCY-TT can be found at:

<http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm>

www.cdc.gov/mmwr/preview/mmwrhtml/mm6203a3.htm?s_cid=mm6203a3_w

<http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/1013-mening-mcv.pdf>

Because MenHibrix is only recommended for certain infants at increased risk for meningococcal disease, Missouri received a very small allocation of this vaccine from CDC. You may place orders in single-dose increments **only** when you have an eligible VFC patient. The Pediatric Vaccine Order form has been updated to include HibMenCY-TT and is located at

<http://health.mo.gov/living/wellness/immunizations/pdf/OrderForm.pdf>. The CPT code for HibMenCY-TT is 90644SL.

Please contact the Missouri VFC program at 800-219-3224 if you have questions or concerns.

